Placebo Auto-Injector A placebo auto-injector device delivers no active pharmaceutical ingredient, serving as a control or inert comparator in clinical studies.
STEQEYMA · Other Ustekinumab binds to the p40 subunit of IL-12 and IL-23, disrupting their signaling and reducing inflammation.
Phase 3 pipeline
AML Y mg · Oncology AML Y mg is an anti-CD28 monoclonal antibody that inhibits T-cell activation.
AZM X mg · Infectious diseases Azithromycin is a macrolide antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit.
AZM X mg + AML Y mg · Cardiovascular AZM (azilsartan) is an angiotensin II receptor blocker and AML (amlodipine) is a calcium channel blocker; together they reduce blood pressure through complementary vasodilatory pathways.
CT-L03 · Immunology / Rheumatology CT-L03 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.
CT-P10 · Immunology / Rheumatology CT-P10 is a monoclonal antibody that binds to and inhibits TNF-alpha, reducing inflammatory signaling in autoimmune and inflammatory diseases.
CT-P13 SC Auto-injector · Immunology CT-P13 SC is a subcutaneous auto-injector formulation of infliximab, a TNF-alpha inhibitor that blocks tumor necrosis factor signaling to reduce inflammation.
CT-P13 SC (Infliximab) · Immunology CT-P13 SC is a subcutaneous formulation of infliximab, a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha to reduce inflammation.
CT-P16 · Oncology CT-P16 is a monoclonal antibody that binds to and blocks programmed death ligand 1 (PD-L1), enhancing anti-tumor immune responses by releasing the inhibition of T cells.
CT-P17 · Oncology CT-P17 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.
CT-P17 SC · Immunology / Rheumatology CT-P17 SC is a subcutaneous formulation of a monoclonal antibody targeting TNF-alpha to reduce inflammatory cytokine signaling.
CT-P17 SC AI (adalimumab) · Immunology CT-P17 SC AI is a subcutaneous adalimumab biosimilar that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.
CT-P39 · Oncology CT-P39 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.
CT-P41 · Oncology CT-P41 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and blocking growth signaling.
CT-P42 · Oncology CT-P42 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.
CT-P43 · Oncology CT-P43 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and blocking growth signaling.
CT-P44(Daratumumab) · Oncology CT-P44 is a monoclonal antibody that binds to CD38 on multiple myeloma cells, triggering their destruction through antibody-dependent cellular cytotoxicity and direct apoptosis.
CT-P47 · Oncology CT-P47 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.
CT-P47 AI (tocilizumab) · Immunology CT-P47 is a biosimilar of tocilizumab that blocks the interleukin-6 (IL-6) receptor to reduce inflammatory signaling.
CT-P47 PFS (tocilizumab) · Immunology CT-P47 is a monoclonal antibody that blocks interleukin-6 (IL-6) receptor, reducing inflammatory signaling in immune-mediated diseases.
CT-P51 · Oncology CT-P51 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
CT-P53 · Oncology CT-P53 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.
CT-P55 · Oncology CT-P55 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and blocking growth signaling.
CT-P6 · Immunology / Rheumatology / Gastroenterology CT-P6 is a monoclonal antibody that binds to and inhibits tumor necrosis factor alpha (TNF-α), reducing inflammatory signaling in autoimmune and inflammatory diseases.
Darzalex Faspro(Daratumumab) · Oncology Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.
EU-approved Cosentyx · Immunology / Dermatology / Rheumatology Cosentyx is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated skin and joint diseases.
EU-approved Humira · Immunology Humira is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha, a key inflammatory cytokine driving autoimmune and inflammatory diseases.
EU-approved Keytruda · Oncology Keytruda is a monoclonal antibody that blocks PD-1 on immune cells, allowing the immune system to recognize and attack cancer cells.
EU-approved Xolair · Immunology / Allergy Xolair is a monoclonal antibody that binds to immunoglobulin E (IgE) and prevents its interaction with high-affinity IgE receptors on mast cells and basophils, thereby reducing allergic cascade activation.
EU-Ocrevus · Immunology EU-Ocrevus is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity.
Humira SC · Immunology Humira SC is a subcutaneous formulation of adalimumab, a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.
US-licensed Humira · Immunology Humira is a monoclonal antibody that targets and binds to tumor necrosis factor-alpha (TNF-alpha), preventing it from interacting with its cell surface receptor and thereby reducing inflammation.
US-licensed Prolia · Osteoporosis Prolia is a human monoclonal antibody that targets RANKL, a protein involved in bone resorption.
US-Ocrevus · Immunology / Oncology US-Ocrevus is a monoclonal antibody that targets CD20 on B cells, depleting them to reduce autoimmune-mediated inflammation.